Guardant Health (NASDAQ: GH) reported Q4 EPS of ($0.50), $0.27 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $281.3 million versus the consensus estimate of $268.98 million.

GUIDANCE:

Guardant Health sees FY2026 revenue of $1.25-1.28 billion, versus the consensus of $1.242 billion.

For earnings history and earnings-related data on Guardant Health (GH) click here.